Cash flow Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
750.57 ^USD	+0.61%		+0.23%	-2.76%

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI

30a5e5acd6e3935fe151c14871a.el4kCrZ9PJqSt8pOf_RUy2nUg4b9XZqwtjoNmzJ3paM.NhNea9c8TcP525I_T7ltogfs-9WZONCF-3d6-l4Y6tsYKm9O9TJ-39uB-g

Published financial data: REGENERON PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	15.79B	11.81B	12.58B	13.69B	13.64B
Other Revenues, Total	281M	365M	536M	515M	703M
Total Revenues	16.07B	12.17B	13.12B	14.2B	14.34B
Cost of Goods Sold, Total	5.35B	5.15B	6.25B	7.1B	7.95B
Gross Profit	10.73B	7.02B	6.86B	7.1B	6.39B
Selling General & Admin Expenses, Total	1.82B	2.12B	2.63B	2.95B	2.7B
Other Operating Expenses	-45.6M	-89.9M	-2.1M	-	-10M
Other Operating Expenses, Total	1.78B	2.03B	2.63B	2.95B	2.69B
Operating Income	8.95B	4.99B	4.23B	4.15B	3.7B
Interest Expense, Total	-57.3M	-59.4M	-73M	-55.2M	-43.8M
Interest And Investment Income	-	160M	496M	711M	717M
Net Interest Expenses	-57.3M	101M	423M	656M	673M
Currency Exchange Gains (Loss)	-	-	-12.9M	-500K	2.4M
Other Non Operating Income (Expenses)	50.2M	59M	-20M	15.8M	988M
EBT, Excl. Unusual Items	8.94B	5.15B	4.62B	4.82B	5.37B
Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	386M	-39.8M	-238M	118M	-10.6M
In Process R&D Expenses	-	-255M	-186M	-101M	-124M
Legal Settlements	-	-	-	-	-
Other Unusual Items	-	-	-	-53.4M	-
EBT, Incl. Unusual Items	9.33B	4.86B	4.2B	4.78B	5.23B
Income Tax Expense	1.25B	520M	246M	367M	726M
Earnings From Continuing Operations	8.08B	4.34B	3.95B	4.41B	4.5B
Net Income to Company	8.08B	4.34B	3.95B	4.41B	4.5B
Net Income - (IS)	8.08B	4.34B	3.95B	4.41B	4.5B
Net Income to Common Incl Extra Items	8.08B	4.34B	3.95B	4.41B	4.5B
Net Income to Common Excl. Extra Items	8.08B	4.34B	3.95B	4.41B	4.5B
Per Share Items
Net EPS - Basic	76.4	40.51	37.05	40.9	43.07
Basic EPS - Continuing Operations	76.4	40.51	37.05	40.9	43.07
Basic Weighted Average Shares Outstanding	106M	107M	107M	108M	105M
Net EPS - Diluted	71.97	38.22	34.77	38.34	41.48
Diluted EPS - Continuing Operations	71.97	38.22	34.77	38.34	41.48
Diluted Weighted Average Shares Outstanding	112M	114M	114M	115M	109M
Normalized Basic EPS	52.86	30.08	27.08	27.9	32.06
Normalized Diluted EPS	49.8	28.38	25.41	26.15	30.88
Dividend Per Share	-	-	-	-	3.52
Payout Ratio	-	-	-	-	8.22
American Depositary Receipts Ratio (ADR)	0.02	0.02	0.02	0.02	0.02
Supplemental Items
EBITDA	9.23B	5.34B	4.65B	4.63B	4.25B
EBITA	8.95B	5.03B	4.33B	4.27B	3.88B
EBIT	8.95B	4.99B	4.23B	4.15B	3.7B
EBITDAR	-	-	4.67B	4.66B	4.28B
Total Revenues (As Reported)	16.07B	12.17B	13.12B	14.2B	14.34B
Effective Tax Rate - (Ratio)	13.41	10.71	5.85	7.68	13.88
Current Domestic Taxes	1.44B	976M	676M	1.08B	1.03B
Current Foreign Taxes	-38.4M	291M	408M	43.1M	479M
Total Current Taxes	1.4B	1.27B	1.08B	1.12B	1.51B
Deferred Domestic Taxes	-424M	-800M	-841M	-940M	-861M
Deferred Foreign Taxes	277M	54M	3.2M	183M	75.3M
Total Deferred Taxes	-147M	-746M	-838M	-757M	-785M
Normalized Net Income	5.59B	3.22B	2.89B	3.01B	3.35B
Interest on Long-Term Debt	56.3M	65.9M	89.4M	90.5M	83.5M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	3.4B	4.12B	4.8B	5.42B	6.12B
Net Rental Expense, Total	-	-	19.2M	36.5M	35.8M
Imputed Operating Lease Interest Expense	-	-	4.03M	5.63M	4.24M
Imputed Operating Lease Depreciation	-	-	15.17M	30.87M	31.56M
Stock-Based Comp., COGS (Total)	317M	407M	489M	544M	545M
Stock-Based Comp., SG&A Exp. (Total)	213M	256M	307M	355M	363M
Stock-Based Comp., Other (Total)	71.8M	61.8M	89.2M	84M	85.4M
Total Stock-Based Compensation	602M	725M	885M	983M	994M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	2.89B	3.11B	2.73B	2.49B	3.12B
Short Term Investments	2.81B	4.64B	8.11B	6.52B	5.49B
Total Cash And Short Term Investments	5.69B	7.74B	10.84B	9.01B	8.61B
Accounts Receivable, Total	5.06B	3.59B	5.32B	5.84B	5.74B
Other Receivables	978M	1.74B	350M	368M	-
Total Receivables	6.04B	5.33B	5.67B	6.21B	5.74B
Inventory	1.95B	2.4B	2.58B	3.09B	3.2B
Prepaid Expenses	332M	411M	387M	348M	469M
Restricted Cash	-	-	-	800K	5.6M
Total Current Assets	14.01B	15.88B	19.48B	18.66B	18.02B
Gross Property Plant And Equipment	4.88B	5.43B	6.25B	7.18B	8.05B
Accumulated Depreciation	-1.4B	-1.67B	-2.02B	-2.37B	-2.68B
Net Property Plant And Equipment	3.48B	3.76B	4.22B	4.82B	5.37B
Long-term Investments	6.88B	6.64B	5.47B	9.06B	10.59B
Other Intangibles, Total	-	916M	1.04B	1.15B	1.26B
Deferred Tax Assets Long-Term	877M	1.72B	2.58B	3.31B	4.08B
Other Long-Term Assets, Total	183M	288M	292M	759M	1.24B
Total Assets	25.43B	29.21B	33.08B	37.76B	40.56B
Liabilities
Accounts Payable, Total	564M	589M	607M	790M	939M
Accrued Expenses, Total	1.59B	2.06B	2.32B	2.28B	2.84B
Current Portion of Leases	720M	-	19M	30.3M	37.8M
Current Income Taxes Payable	326M	300K	-	213M	-
Unearned Revenue Current, Total	442M	478M	482M	628M	553M
Other Current Liabilities	287M	10.5M	-	-	-
Total Current Liabilities	3.93B	3.14B	3.42B	3.94B	4.37B
Long-Term Debt	1.98B	1.98B	1.98B	1.98B	1.99B
Long-Term Leases	-	720M	789M	924M	949M
Unearned Revenue Non Current	73.3M	69.8M	127M	186M	209M
Other Non Current Liabilities	680M	638M	785M	1.37B	1.79B
Total Liabilities	6.67B	6.55B	7.11B	8.41B	9.3B
Common Stock, Total	100K	100K	100K	100K	100K
Additional Paid In Capital	8.09B	9.95B	11.35B	12.86B	14B
Retained Earnings	18.97B	23.31B	27.26B	31.67B	35.8B
Treasury Stock	-8.26B	-10.35B	-12.56B	-15.17B	-18.61B
Comprehensive Income and Other	-26.2M	-239M	-80.9M	-7.9M	77.5M
Total Common Equity	18.77B	22.66B	25.97B	29.35B	31.26B
Total Equity	18.77B	22.66B	25.97B	29.35B	31.26B
Total Liabilities And Equity	25.43B	29.21B	33.08B	37.76B	40.56B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	106M	107M	107M	107M	103M
ECS Total Common Shares Outstanding	107M	107M	107M	107M	103M
Book Value / Share	176.11	211.81	242.47	274.08	304.65
Tangible Book Value	18.77B	21.75B	24.93B	28.2B	30B
Tangible Book Value Per Share	176.11	203.26	232.78	263.35	292.39
Total Debt	2.7B	2.7B	2.79B	2.94B	2.97B
Net Debt	-9.83B	-11.63B	-13.45B	-14.97B	-15.89B
Debt Equivalent Oper. Leases	-	-	154M	292M	286M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	722M	818M	789M	880M	642M
Inventories - Work In Process, Total	707M	963M	1.12B	1.34B	1.64B
Inventories - Finished Goods, Total	73.7M	98.6M	147M	140M	190M
Inventories - Others	448M	522M	522M	726M	728M
Land - (BS)	248M	264M	283M	288M	279M
Buildings, Total	2.09B	2.27B	2.42B	2.57B	3.11B
Machinery, Total	1.66B	1.8B	1.94B	2.15B	2.29B
Full Time Employees	10.37K	11.85K	13.45K	15.11K	15.41K

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	8.08B	4.34B	3.95B	4.41B	4.5B
Depreciation & Amortization - CF	286M	304M	329M	354M	365M
Amortization of Goodwill and Intangible Assets - (CF)	-	37.6M	92.2M	129M	179M
Depreciation & Amortization, Total	286M	341M	421M	483M	544M
(Gain) Loss on Sale of Investments - (CF)	-387M	36.8M	266M	-118M	-946M
Asset Writedown & Restructuring Costs	-	195M	-	12.6M	-
Stock-Based Compensation (CF)	602M	725M	885M	983M	994M
Other Operating Activities, Total	422M	-378M	-838M	-734M	-650M
Change In Accounts Receivable	-1.93B	708M	-339M	-554M	498M
Change In Inventories	-494M	-696M	-272M	-620M	-275M
Change In Accounts Payable	866M	-138M	599M	735M	737M
Change in Unearned Revenues	-120M	32.4M	37.9M	228M	-51.7M
Change in Other Net Operating Assets	-241M	-149M	-120M	-408M	-375M
Cash from Operations	7.08B	5.01B	4.59B	4.42B	4.98B
Capital Expenditure	-552M	-590M	-719M	-756M	-898M
Sale of Property, Plant, and Equipment	-	-	-	20.1M	-
Cash Acquisitions	-	-230M	-54.9M	-16.5M	-3.3M
Sale (Purchase) of Intangible assets	-	-1.03B	-208M	-126M	-315M
Investment in Marketable and Equity Securities, Total	-4.83B	-1.94B	-2.2B	-1.59B	588M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-5.38B	-3.78B	-3.19B	-2.47B	-629M
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	1.67B	1.52B	1.15B	1.47B	636M
Repurchase of Common Stock	-2.68B	-2.53B	-2.94B	-3.63B	-3.97B
Common Dividends Paid	-	-	-	-	-370M
Common & Preferred Stock Dividends Paid	-	-	-	-	-370M
Other Financing Activities, Total	-	-	-	-33.4M	-10.3M
Cash from Financing	-1.01B	-1.01B	-1.79B	-2.2B	-3.72B
Foreign Exchange Rate Adjustments	-	-	-400K	-700K	300K
Net Change in Cash	691M	221M	-382M	-249M	635M
Supplemental Items
Cash Interest Paid	55.8M	53.7M	73.1M	52.6M	41.6M
Cash Income Tax Paid (Refund)	1.22B	1.5B	870M	743M	1.25B
Levered Free Cash Flow	4.28B	2.64B	2.76B	2.64B	3.26B
Unlevered Free Cash Flow	4.32B	2.68B	2.81B	2.67B	3.29B
Change In Net Working Capital	1.61B	-107M	217M	504M	-648M
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	26.25	11.42	8.49	7.31	5.91
Return on Total Capital	31.78	13.33	9.76	8.49	6.96
Return On Equity %	54.21	20.94	16.26	15.95	14.86
Return on Common Equity	54.21	20.94	16.26	15.95	14.86
Margin Analysis
Gross Profit Margin %	66.74	57.67	52.32	49.99	44.57
SG&A Margin	11.35	17.38	20.06	20.8	18.82
EBITDA Margin %	57.45	43.83	35.48	32.59	29.6
EBITA Margin %	55.67	41.33	32.98	30.09	27.06
EBIT Margin %	55.67	41.03	32.27	29.19	25.81
Income From Continuing Operations Margin %	50.25	35.64	30.14	31.07	31.41
Net Income Margin %	50.25	35.64	30.14	31.07	31.41
Net Avail. For Common Margin %	50.25	35.64	30.14	31.07	31.41
Normalized Net Income Margin	34.76	26.46	22.03	21.2	23.38
Levered Free Cash Flow Margin	26.63	21.69	21.06	18.56	22.72
Unlevered Free Cash Flow Margin	26.85	22	21.41	18.8	22.91
Asset Turnover
Asset Turnover	0.75	0.45	0.42	0.4	0.37
Fixed Assets Turnover	4.79	3.36	3.26	3.14	2.82
Receivables Turnover (Average Receivables)	3.87	2.73	2.43	2.46	2.28
Inventory Turnover (Average Inventory)	2.76	2.37	2.51	2.51	2.53
Short Term Liquidity
Current Ratio	3.56	5.06	5.69	4.73	4.13
Quick Ratio	2.98	4.16	4.82	3.86	3.28
Operating Cash Flow to Current Liabilities	1.8	1.6	1.34	1.12	1.14
Days Sales Outstanding (Average Receivables)	94.44	133.62	150	148.98	159.92
Days Outstanding Inventory (Average Inventory)	132.05	154.18	145.37	146.03	144.33
Average Days Payable Outstanding	35.26	37.56	33.92	33.58	39.12
Cash Conversion Cycle (Average Days)	191.23	250.23	261.45	261.44	265.14
Long Term Solvency
Total Debt/Equity	14.38	11.92	10.74	10.01	9.51
Total Debt / Total Capital	12.58	10.65	9.7	9.1	8.68
LT Debt/Equity	10.55	11.92	10.67	9.91	9.39
Long-Term Debt / Total Capital	9.22	10.65	9.64	9.01	8.57
Total Liabilities / Total Assets	26.21	22.42	21.48	22.26	22.93
EBIT / Interest Expense	156.14	84.07	57.99	75.09	84.52
EBITDA / Interest Expense	161.13	89.82	64.02	84.5	97.75
(EBITDA - Capex) / Interest Expense	151.5	79.89	54.18	70.81	77.24
Total Debt / EBITDA	0.29	0.51	0.6	0.63	0.69
Net Debt / EBITDA	-1.06	-2.18	-2.88	-3.21	-3.71
Total Debt / (EBITDA - Capex)	0.31	0.57	0.71	0.75	0.88
Net Debt / (EBITDA - Capex)	-1.13	-2.45	-3.4	-3.83	-4.7
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	89.14	-24.26	7.76	8.27	0.99
Gross Profit, 1 Yr. Growth %	131.06	-34.84	-2.25	3.46	-9.97
EBITDA, 1 Yr. Growth %	142.18	-42.51	-12.77	-0.56	-8.26
EBITA, 1 Yr. Growth %	150.15	-44.06	-14.04	-1.19	-9.2
EBIT, 1 Yr. Growth %	150.15	-44.48	-15.23	-2.08	-10.69
Earnings From Cont. Operations, 1 Yr. Growth %	129.86	-46.28	-8.87	11.61	2.09
Net Income, 1 Yr. Growth %	129.86	-46.28	-8.87	11.61	2.09
Normalized Net Income, 1 Yr. Growth %	149.34	-42.66	-10.29	4.18	11.39
Diluted EPS Before Extra, 1 Yr. Growth %	135.81	-46.89	-9.03	10.27	8.19
Accounts Receivable, 1 Yr. Growth %	62.56	-29.12	5.86	10.29	-7.58
Inventory, 1 Yr. Growth %	1.81	23.09	7.44	19.64	3.68
Net Property, Plant and Equip., 1 Yr. Growth %	8.09	8.06	10.18	14.03	11.4
Total Assets, 1 Yr. Growth %	48.19	14.86	13.23	14.14	7.41
Tangible Book Value, 1 Yr. Growth %	70.23	15.92	14.65	13.12	6.36
Common Equity, 1 Yr. Growth %	70.23	20.75	14.6	13.02	6.48
Cash From Operations, 1 Yr. Growth %	170.47	-29.18	-8.39	-3.78	12.63
Capital Expenditures, 1 Yr. Growth %	-10.2	6.92	21.78	5.19	18.85
Levered Free Cash Flow, 1 Yr. Growth %	276.49	-38.72	5.12	-4.59	23.62
Unlevered Free Cash Flow, 1 Yr. Growth %	268.12	-38.37	5.37	-4.91	23.04
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	56.55	19.69	-9.66	8.01	4.57
Gross Profit, 2 Yr. CAGR %	79.14	21.82	-20.19	0.56	-3.49
EBITDA, 2 Yr. CAGR %	95.32	16.96	-29.18	-6.86	-4.49
EBITA, 2 Yr. CAGR %	101.21	17.18	-30.65	-7.84	-5.28
EBIT, 2 Yr. CAGR %	101.21	16.74	-31.4	-8.89	-6.48
Earnings From Cont. Operations, 2 Yr. CAGR %	95.36	11.13	-30.03	0.85	6.74
Net Income, 2 Yr. CAGR %	95.36	11.13	-30.03	0.85	6.74
Normalized Net Income, 2 Yr. CAGR %	96.69	17.98	-28.28	-3.33	7.68
Diluted EPS Before Extra, 2 Yr. CAGR %	97.45	11.91	-30.49	0.16	9.22
Accounts Receivable, 2 Yr. CAGR %	37.05	7.35	2.52	7.86	4.09
Inventory, 2 Yr. CAGR %	17.41	11.95	15	13.37	11.37
Net Property, Plant and Equip., 2 Yr. CAGR %	9.76	8.08	10.14	12.09	12.71
Total Assets, 2 Yr. CAGR %	31.07	30.47	14.04	13.69	10.73
Tangible Book Value, 2 Yr. CAGR %	30.09	40.45	15.28	13.88	9.69
Common Equity, 2 Yr. CAGR %	30.09	43.37	17.64	13.81	9.7
Cash From Operations, 2 Yr. CAGR %	70.71	38.4	-19.46	-6.11	4.1
Capital Expenditures, 2 Yr. CAGR %	13.34	-2.01	14.11	13.18	11.81
Levered Free Cash Flow, 2 Yr. CAGR %	73.35	48.86	-19.93	0.15	8.6
Unlevered Free Cash Flow, 2 Yr. CAGR %	72.94	47.71	-19.61	0.09	8.17
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	46.18	22.9	15.57	-4.04	5.62
Gross Profit, 3 Yr. CAGR %	48.74	28.06	13.2	-12.98	-3.08
EBITDA, 3 Yr. CAGR %	50.98	30.15	6.07	-20.7	-7.33
EBITA, 3 Yr. CAGR %	52.26	31.56	5.68	-21.97	-8.29
EBIT, 3 Yr. CAGR %	52.26	31.23	4.93	-22.76	-9.5
Earnings From Cont. Operations, 3 Yr. CAGR %	48.93	27.04	4.02	-18.25	1.26
Net Income, 3 Yr. CAGR %	48.93	27.04	4.02	-18.25	1.26
Normalized Net Income, 3 Yr. CAGR %	51.02	30.65	7.68	-18.77	1.35
Diluted EPS Before Extra, 3 Yr. CAGR %	50.08	27.45	4.44	-18.94	2.77
Accounts Receivable, 3 Yr. CAGR %	30.58	10.01	19.55	4.93	4.55
Inventory, 3 Yr. CAGR %	19.23	19.27	10.42	16.52	10.04
Net Property, Plant and Equip., 3 Yr. CAGR %	10.57	9.19	9.45	11.42	11.86
Total Assets, 3 Yr. CAGR %	29.42	25.43	24.45	14.08	11.56
Tangible Book Value, 3 Yr. CAGR %	28.93	25.17	31.26	14.56	11.32
Common Equity, 3 Yr. CAGR %	28.93	26.9	33.06	16.08	11.31
Cash From Operations, 3 Yr. CAGR %	47.76	27.32	20.62	-14.54	-0.24
Capital Expenditures, 3 Yr. CAGR %	12.94	11.16	5.35	11.05	15.04
Levered Free Cash Flow, 3 Yr. CAGR %	46.75	22.86	32.35	-15.11	7.43
Unlevered Free Cash Flow, 3 Yr. CAGR %	46.53	22.89	31.78	-14.98	7.22
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	27.02	15.7	20.58	16.71	11.04
Gross Profit, 5 Yr. CAGR %	33.72	15.6	16.06	16.26	6.21
EBITDA, 5 Yr. CAGR %	45.1	19.11	11.65	13.84	1.71
EBITA, 5 Yr. CAGR %	46.39	19.33	11.28	14.1	1.15
EBIT, 5 Yr. CAGR %	46.39	19.15	10.8	13.41	0.2
Earnings From Cont. Operations, 5 Yr. CAGR %	55.25	29.34	10.09	15.84	5.1
Net Income, 5 Yr. CAGR %	55.25	29.34	10.09	15.84	5.1
Normalized Net Income, 5 Yr. CAGR %	46.17	19.92	12.24	15.82	7.7
Diluted EPS Before Extra, 5 Yr. CAGR %	56.35	29.88	10.31	15.74	6.33
Accounts Receivable, 5 Yr. CAGR %	25.71	11.88	18.54	16.76	13.03
Inventory, 5 Yr. CAGR %	37.34	27.03	17.52	16.88	10.8
Net Property, Plant and Equip., 5 Yr. CAGR %	10.82	9.79	10.4	10.76	10.74
Total Assets, 5 Yr. CAGR %	29.54	27.23	23.03	20.59	18.77
Tangible Book Value, 5 Yr. CAGR %	33.36	28.76	23.28	20.53	22.16
Common Equity, 5 Yr. CAGR %	33.36	29.83	24.29	21.49	23.17
Cash From Operations, 5 Yr. CAGR %	36.65	30.86	15.92	12.71	13.72
Capital Expenditures, 5 Yr. CAGR %	1.52	16.7	13.41	11.96	7.89
Levered Free Cash Flow, 5 Yr. CAGR %	33.17	23.91	15.33	13.11	22.28
Unlevered Free Cash Flow, 5 Yr. CAGR %	33.28	23.83	15.41	13.1	21.77